Janel increases acquisition credit facility commitments by $15 million
JANL•Janel increased commitments under its acquisition credit facility by $15 million, with lenders immediately funding $11 million toward its EnCor Biotechnology acquisition.
1. Facility amendment
Janel increased commitments under its senior secured credit agreement by $15 million on October 16, 2026. Lenders immediately funded $11 million, which was used toward the EnCor Biotechnology acquisition on October 20. Janel subsidiary Antibodies Incorporated paid $11.96 million in cash and issued EnCor a $5.04 million subordinated promissory note. The amendment added an excess cash flow mandatory prepayment provision, waived acquisition restrictions, and made EnCor a borrower under the facility upon completion.
